Onswik is insulin efsitora alfa-gobe, a once-weekly basal insulin approved for adults with type 2 diabetes. The September 2026 US label lists U-500 and U-1000 KwikPens.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Onswik is insulin efsitora alfa-gobe, a once-weekly basal insulin approved for adults with type 2 diabetes. The September 2026 US label lists U-500 and U-1000 KwikPens. Lilly’s site says pens are coming in the coming months, so approval should not be described as confirmed local supply.
Onswik provides prolonged basal insulin action. Concentration and pen increments differ by presentation. The starting dose and later maintenance schedule are not interchangeable.
Onswik is for adult type 2 diabetes. It is not recommended for type 1 diabetes because of increased severe low-glucose risk. Use during pregnancy or breastfeeding is not recommended. The clinician reviews whether monitoring and weekly-dose tracking are safe for you.
Review the exact daily basal insulin regimen and glucose data. Confirm product access before arranging a change. The prescriber chooses the initial dose and later weekly dose according to the Onswik label. Train on the exact pen and record each injection day. A daily dose multiplied by seven is not a safe self-conversion rule.
Bring basal and mealtime insulin labels, dose history, CGM or meter data, kidney results, and low-glucose episodes. Mention pregnancy, breastfeeding, or acute illness.
Never share the pen or draw its insulin into a syringe. Dosing errors can cause serious prolonged hypoglycemia. Severe low glucose or an accidental extra dose needs urgent medical advice. Weekly basal insulin may still be used alongside mealtime insulin when prescribed.
Monitor glucose closely during changes and report lows promptly. Do not repeat a dose when uncertain whether it was already given. Keep current insulin until a clinician supplies a specific transition plan.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
No. Keep the prescribed current insulin until the clinician supplies a specific transition plan and the new product can be obtained. Approval or launch news is not a reason to interrupt diabetes treatment.
The current US Awiqli and Onswik indications are for adults with type 2 diabetes. Onswik is specifically not recommended for type 1 diabetes because of increased severe hypoglycemia risk. Do not replace a type 1 regimen with weekly insulin without specialist care.
No. Weekly insulin is basal or background treatment. Some people still need mealtime insulin or other diabetes medicines. The clinician reviews the whole regimen and glucose pattern before changing any part.
No. Initial switch doses, later weekly doses, timing, and monitoring differ by product and prior regimen. Multiplying the daily dose by seven yourself can cause dangerous low or high glucose. The prescriber must write the exact transition plan.
Do not repeat an injection when you cannot confirm whether it was taken. Check the written dose record and contact the clinician for product-specific advice. Monitor glucose as directed. An accidental extra dose can cause prolonged serious low glucose.
A weekly basal insulin may be self-injected after appropriate training when the prescription and care arrangement allow it. Confirm who teaches the exact pen and reviews glucose. Weekly dosing does not mean that no follow-up is needed.
These numbers describe concentration: U-500 contains 500 insulin units per mL and U-1000 contains 1,000 units per mL. They are not your prescribed weekly dose. The U-500 pen selects doses in 5-unit increments; the U-1000 pen uses 10-unit increments. Read the dose in the pen’s dose window and follow the instructions for your exact pen. Do not count clicks to convert a dose or draw insulin from the pen into a syringe. Ask the prescriber to write the dose and the care team to teach the correct pen before the first injection.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
